Insulet (PODD) Projected to Announce Earnings on Wednesday

Insulet (NASDAQ:PODD) is anticipated to announce its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect Insulet to announce earnings of $1.45 per share and revenue of $787.4170 million for the quarter. Insulet has set its FY 2026 guidance at 6.210- EPS. Investors may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:00 AM ET.

Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, topping the consensus estimate of $1.19 by $0.23. The company had revenue of $761.70 million during the quarter, compared to analysts’ expectations of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The business’s revenue for the quarter was up 33.9% on a year-over-year basis. During the same period last year, the company posted $1.02 earnings per share. On average, analysts expect Insulet to post $6 EPS for the current fiscal year and $8 EPS for the next fiscal year.

Insulet Stock Performance

Insulet stock opened at $167.47 on Wednesday. Insulet has a fifty-two week low of $138.79 and a fifty-two week high of $354.88. The firm’s 50 day simple moving average is $154.59 and its 200-day simple moving average is $200.20. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81. The company has a market cap of $11.60 billion, a P/E ratio of 38.95, a price-to-earnings-growth ratio of 1.15 and a beta of 1.11.

Insider Buying and Selling

In other news, Director Timothy C. Stonesifer bought 2,790 shares of the company’s stock in a transaction on Wednesday, June 3rd. The shares were bought at an average cost of $143.51 per share, with a total value of $400,392.90. Following the transaction, the director directly owned 9,041 shares in the company, valued at approximately $1,297,473.91. This trade represents a 44.63% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.36% of the stock is owned by company insiders.

Institutional Investors Weigh In On Insulet

Several institutional investors have recently made changes to their positions in PODD. RTW Investments LP bought a new stake in shares of Insulet in the 4th quarter valued at approximately $92,264,000. AQR Capital Management LLC raised its position in Insulet by 161.6% during the fourth quarter. AQR Capital Management LLC now owns 459,115 shares of the medical instruments supplier’s stock valued at $130,499,000 after acquiring an additional 283,643 shares in the last quarter. Worldquant Millennium Advisors LLC bought a new position in Insulet during the second quarter valued at approximately $80,082,000. Squarepoint Ops LLC lifted its stake in Insulet by 11,905.8% in the third quarter. Squarepoint Ops LLC now owns 227,270 shares of the medical instruments supplier’s stock valued at $70,165,000 after acquiring an additional 225,377 shares during the last quarter. Finally, Qube Research & Technologies Ltd lifted its stake in Insulet by 37.3% in the third quarter. Qube Research & Technologies Ltd now owns 574,365 shares of the medical instruments supplier’s stock valued at $177,324,000 after acquiring an additional 156,009 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on PODD shares. Stifel Nicolaus decreased their price objective on shares of Insulet from $250.00 to $225.00 and set a “buy” rating for the company in a research note on Friday, July 10th. Benchmark reissued a “buy” rating on shares of Insulet in a research note on Wednesday, May 27th. Oppenheimer cut their target price on shares of Insulet from $300.00 to $210.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Barclays reduced their target price on Insulet from $286.00 to $198.00 and set an “underweight” rating for the company in a report on Thursday, May 7th. Finally, Truist Financial decreased their target price on Insulet from $219.00 to $210.00 and set a “buy” rating for the company in a research report on Monday, July 13th. Twenty-one equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $233.38.

Trending Headlines about Insulet

Here are the key news stories impacting Insulet this week:

• Negative Sentiment: Multiple law firms are promoting a securities-fraud class action against Insulet and certain senior executives. The lawsuits allege that the company misrepresented the safety of its Omnipod products and failed to disclose manufacturing deficiencies. These are allegations, not established findings. PODD Class Reminder article
• Negative Sentiment: The litigation follows a stock decline of more than 6% reportedly triggered by disclosures involving the safety of Insulet’s Omnipod products. If the claims gain traction, potential costs could include legal expenses, settlements, damages, regulatory scrutiny and reputational harm. PODD Shareholder Alert article
• Negative Sentiment: One shareholder alert highlights an alleged $3.7 million sale of Insulet stock by executive Eric Benjamin before two medical-device corrections. Plaintiffs may use the timing to support claims of inadequate disclosure, although the allegations have not been proven. Executive accountability shareholder alert
• Neutral Sentiment: The federal class action is pending in the District of Massachusetts, with proposed class periods generally covering purchases from February 21 or May 21, 2025 through May 26, 2026. Investors have until August 31, 2026 to seek appointment as lead plaintiff. The deadline is procedural and does not determine Insulet’s liability. Pomerantz class action article

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.